Cardiovascular effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists or liraglutide in the EMPRISE study

Norbert Pötschke,Phyo T. Htoo,Helen Tesfaye,Julie M. Paik,Deborah J. Wexler,Mehdi Najafzadeh,Robert J. Glynn,Anouk Déruaz‐Luyet,Soulmaz Fazeli Farsani,Lisette Koeneman,Sebastian Schneeweiß,Elisabetta Patorno

Diabetologie Und Stoffwechsel（2023）

引用 0|浏览2

暂无评分

摘要

Question How does the cardiovascular effectiveness of empagliflozin compare to the one from glucagon-like peptide-1 receptor agonists or liraglutide in a real-world US population?

查看译文

关键词

cardiovascular effectiveness,liraglutide,glucagon-like

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要